Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 21785464 
Ratushny V, et al. (2012) Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene 31, 1217-27 21785464
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T288-p - AurA (human)
Orthologous residues
AurA (human): T288‑p, AurA (mouse): T279‑p, AurA (rat): T281‑p, AurA (pig): T288‑p, AurA (frog): T295‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  ovarian cancer
 Relevant cell lines - cell types - tissues:  OVCAR10 (ovarian), OVCAR5 (ovarian)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
dasatinib nocodazole no effect upon treatment-induced increase

T232-p - AurB (human)
Orthologous residues
AurB (human): T232‑p, AurB (mouse): T237‑p, AurB (rat): T235‑p, AurB (pig): T232‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  ovarian cancer
 Relevant cell lines - cell types - tissues:  OVCAR10 (ovarian), OVCAR5 (ovarian)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
dasatinib nocodazole no effect upon treatment-induced increase

Y419-p - Src (human)
Orthologous residues
Src (human): Y419‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  ovarian cancer
 Relevant cell lines - cell types - tissues:  OVCAR10 (ovarian), OVCAR5 (ovarian)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dasatinib decrease
MNLN8237 decrease slight decrease
MNLN8237 dasatinib augment treatment-induced decrease
PHA-680632 decrease
PHA-680632 dasatinib augment treatment-induced decrease
nocodazole increase
dasatinib nocodazole inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.